Pliant Therapeutics
PLRX
81 hedge funds and large institutions have $894M invested in Pliant Therapeutics in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
7% more funds holding
Funds holding: 76 → 81 (+5)
0.42% less ownership
Funds ownership: 85.95% → 85.53% (-0.42%)
26% less capital invested
Capital invested by funds: $1.21B → $894M (-$314M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $189K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.26M |
| 2 |
FIM
Fernwood Investment Management
Quincy,
Massachusetts
|
+$4.7M |
| 3 |
BDFN
Bond & Devick Financial Network
St. Louis Park,
Minnesota
|
+$3.74M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.23M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$8.54M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.02M |
| 3 |
BlackRock
New York
|
-$3.65M |
| 4 |
Bank of New York Mellon
New York
|
-$3.63M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.58M |
PLRX Hedge Fund Activity: Q2 2021 in Review
81 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2021, worth a combined $894M — down 26% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PLRX positions and 7 closed out — a net gain of 5 holders — while 27 added to existing stakes and 23 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.26M. The largest seller was Farallon Capital Management, cutting an estimated $8.54M.
- 81 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2021, up from 76 in Q1 2021.
- Funds reported $894M of Pliant Therapeutics stock for Q2 2021, down 26% quarter-over-quarter.
- 12 funds opened new Pliant Therapeutics positions in Q2 2021 and 7 closed out, a net change of +5 holders.
- The largest Pliant Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $5.26M added.
- The largest Pliant Therapeutics seller in Q2 2021 was Farallon Capital Management, an estimated $8.54M sold.
Based on aggregated 13F filings for Q2 2021.